Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera

JACC: Heart Failure

Volumn 4, Issue 5, 2016, Pages 403-408

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Heart failure; Neprilysin; Sacubitril valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; PLACEBO; POTASSIUM; SACUBITRIL PLUS VALSARTAN;

CLINICAL TRIAL (TOPIC); DEFIBRILLATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MEDICAL DECISION MAKING; MORTALITY; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84963959742     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.02.012     Document Type: Review

References (36)

1. Booker MK. The dangers of gullible reading: narrative as seduction in García Márquez' Love in the Time of Cholera. In: Studies in 20th Century Literature, volume 17, issue 2. Article 3. Available at: . Accessed February 4, 2016. http://dx.doi.org/10.4148/2334-4415.1321.
2. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435. CONSENSUS Trial Study Group.
3. Ong H.T., Ong L.M., Ho J.J. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients at high risk of cardiovascular events: a meta-analysis of 10 randomised placebo-controlled trials. ISRN Cardiol 2013, 2013:478597.
4. Baker W.L., Coleman C.I., Kluger J., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009, 151:861-871.
5. Cheng J., Zhang W., Zhang X., et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014, 174:773-785.
6. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302. SOLVD Investigators.
7. Cohn J.N., Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
8. Maggioni A.P., Anand I., Gottlieb S.O., Latini R., Tognoni G., Cohn J.N. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002, 40:1414-1421. for the Val-HeFT Investigators.
9. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776. CHARM Investigators and Committees.
10. Abdulla J., Abildstrom S.Z., Christensen E., Kober L., Torp-Pedersen C. A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction. Eur J Heart Fail 2004, 6:927-935.
11. O'Meara E., Solomon S., McMurray J., et al. Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2004, 25:1920-1926.
12. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
13. Majani G., Giardini A., Opasich C., et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. J Card Fail 2005, 11:253-259.
14. Heywood J.T., Fonarow G.C., Yancy C.W., et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail 2010, 3:596-605.
15. Peters-Klimm F., Müller-Tasch T., Schellberg D., et al. Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clin Res Cardiol 2008, 97:244-252.
16. Kasje W.N., Denig P., de Graeff P.A., Haaijer-Ruskamp F.M. Perceived barriers for treatment of chronic heart failure in general practice: are they affecting performance?. BMC Fam Pract 2005, 6:19.
17. Hobbs F.D., Jones M.I., Allan T.F., Wilson S., Tobias R. European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Eur Heart J 2000, 21:1877-1887.
18. Chin M.H., Wang J.C., Zhang J.X., Lang R.M. Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure. Effect of physician specialty and patient characteristics. J Gen Intern Med 1997, 12:563-566.
19. Crespo-Leiro M.G., Segovia-Cubero J., González-Costello J., et al. Adherence to the ESC heart failure treatment guidelines in Spain: ESC heart failure long-term registry. Rev Esp Cardiol (Engl Ed) 2015, 68:785-793.
20. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239. American College of Cardiology Foundation, American Heart Association Task Force on practice guidelinesAmerican Heart Association Task Force on practice guidelines.
21. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
22. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999, 100:2312-2318.
23. Massie B.M., Armstrong P.W., Cleland J.G., et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 2001, 161:165-171.
24. Konstam M.A., Neaton J.D., Dickstein K., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374:1840-1848. HEAAL Investigators.
25. Gheorghiade M., Böhm M., Greene S.J., et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013, 309:1125-1135. ASTRONAUT Investigators and Coordinators.
26. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004. PARADIGM-HF Investigators and Committees.
27. Desai A.S., McMurray J.J., Packer M., et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015, 36:1990-1997.
28. Vardeny O., Claggett B., McMurray J.J.V., et al. Efficacy of LCZ696 persists at lower than target doses in the PARADIGM-HF Trial (abstr). J Cardiac Failure 2015, 21:S9-S10. for the PARADIGM-HF Investigators.
29. Packer M., McMurray J.J., Desai A.S., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015, 131:54-61. PARADIGM-HF Investigators and Coordinators.
30. Rademaker M.T., Charles C.J., Espiner E.A., Nicholls M.G., Richards A.M., Kosoglou T. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol 1998, 31:116-125.
31. Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D., Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004, 17:103-111.
32. Krum H., Roecker E.B., Mohacsi P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003, 289:712-718. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.
33. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005, 46:425-431. for the EPHESUS Investigators.
34. McMurray J.J., Young J.B., Dunlap M.E., et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006, 151:985-991. CHARM Investigators.
35. Krum H., Shi H., Pitt B., et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail 2013, 6:711-718. EMPHASIS-HF Study Group.
36. Ghali J.K., Dunselman P., Waagstein F., et al. Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis. J Card Fail 2004, 10:452-459.